The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock
- PMID: 34895482
- DOI: 10.1016/S2213-2600(21)00488-4
The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock
Conflict of interest statement
BNT reports serving on the advisory board for Abbott and receiving research grants from Boston Scientific and Inari Medical. WBB reports consultancy work for Boston Scientific, Abbott, Medtronic, and V-Wave. MWS declares no competing interests.
Comment on
-
Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.Lancet Respir Med. 2022 Mar;10(3):247-254. doi: 10.1016/S2213-2600(21)00439-2. Epub 2021 Dec 8. Lancet Respir Med. 2022. PMID: 34895483 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
